Everlywell is a telehealth and at-home diagnostic company that offers a broad suite of lab tests, virtual care visits, and wellness products directly to consumers and through employer programs. This evergreen profile explains how the business makes money, how experts think about its valuation, and what verifiable context exists around its net worth as a privately held company. Rather than a single public market price, Everlywell’s net worth is estimated through funding rounds, revenue benchmarks, and industry multiples. Below you will find a concise factual summary, a breakdown of value indicators, and a long-form explanation intended to remain useful as the business and telehealth markets evolve.
What Everlywell Does and How It Generates Revenue
Everlywell sells at-home test kits for hormones, vitamins, infectious disease, heart health, and women’s health, combined with telehealth visits that let members discuss results with nurse practitioners and physicians. Revenue comes from three main streams: the direct-toconsumer shop, recurring subscription programs like Everlywell Health+, and enterprise wellness programs for employers and health systems. The company states it has served hundreds of thousands of members across categories such as sexual health, fertility support, and chronic condition monitoring. Because Everlywell is private, it does not publish quarterly revenue or margin data, so valuation estimates rely on disclosed funding totals, secondary share prices in late-stage rounds, and reported membership figures.
How Private Company Net Worth Is Estimated
For private companies like Everlywell, net worth is not a single market-mandated number. Instead, analysts build ranges using the last known funding valuation, trailing revenue multiples, and discounted cash flow models based on projected telehealth demand. Investors and financial journalists typically triangulate between a company’s last priced funding round, executive commentary, and comparable public peers in digital health. Those methods can differ widely, so any Everlywell net worth figure should be treated as an informed estimate rather than a precise, audited balance sheet value. The table below summarizes the most reliable verified inputs available from public sources.
| Attribute | Verified Detail or Estimate | Source Type |
|---|---|---|
| Company Status | Private, venture funded | Corporate disclosures |
| Last Known Funding Round | Series D in 2021, raised $430 million | SEC filings and company announcements |
| Post-Money Valuation at Series D | Reported over $1 billion (unicorn status) | Business press and investor sources |
| Revenue Trajectory | Estimated mid-double-digit growth YoY, consistent with telehealth peers | Analyst notes and executive commentary |
| Membership Scale | Hundreds of thousands of members across direct and enterprise channels | Company updates and partnership announcements |
| Industry Comparison | Telehealth diagnostics positioned amid 2020–2022 boom and normalization | Third‑party market research |
Everlywell Funding History and Valuation Context
Everlywell raised several large rounds during the telehealth surge, culminating in a Series D in 2021 that pushed the company into unicorn territory with a reported valuation above $1 billion. After that peak, the broader digital health market cooled, and later private transactions and secondary share sales implied a range of discounts to that high-water mark. When people ask about Everlywell’s net worth, they are usually asking how those valuation moves translate into today’s realistic enterprise value. The current estimate often falls into a band significantly below the 2021 peak but still substantial, reflecting revenue run rate, contracted customer bases, and ongoing ecommerce demand.
Key Funding and Valuation Milestones
- Seed and early rounds (2015–2018): Established product-market fit for at-home testing.
- Series C (2019): Expanded telehealth capabilities and national employer partnerships.
- Series D (2021): Raised $430 million at a valuation over $1 billion, signaling peak enthusiasm.
- 2022–2024: Secondary transactions and hiring adjustments reflected a more cautious telehealth environment.
Revenue, Margins, and Business Model Efficiency
Everlywell’s business model combines high-margin consumables (test kits) with recurring revenue from subscriptions and enterprise contracts, which together should support operating leverage if utilization and retention stay strong. Because the company does not disclose gross margin or operating income, outside analysts infer profitability trajectories from cohort retention, average revenue per user, and the mix between one-time tests and recurring services. In a mature telehealth diagnostics operation, contribution margin, efficient logistics, and low customer acquisition cost become primary drivers of long-term value. By contrast, heavy marketing spend or high churn would pressure any implied net worth estimate.
How Its Net Worth Compares to Public Comp peers
Public telehealth and diagnostics companies trade at varied multiples tied to growth, regulation, and payer mix. Analysts sometimes benchmark Everlywell to players in at-home testing and virtual care, using metrics such as price-to-sales and enterprise value-to-EBITDA. Because Everlywell is private, side-by-side comparisons necessarily involve adjustments for scale, profitability, and market depth. The graphic below outlines a simple framework for comparing the company to certain public peers on a relative basis.
Comparative Valuation Framework (Conceptual)
| Company Attribute | Everlywell (Estimate) | Public Peer A | Public Peer B |
|---|---|---|---|
| Primary Model | At-home tests + telehealth | At-home tests + telehealth | Telehealth + diagnostics labs |
| Valuation Approach | Revenue multiple range from late-stage rounds | Public market EV/Sales | Public market EV/Sales |
| Growth Profile | Mid-double-digit revenue growth | High single to low-double digit | Low single digit or flat |
| Profitability Status | Not disclosed; estimated contribution margin positive and improving | Selective profit or path to profit | Mixed margins across segments |
| Liquidity | Private, secondary markets and occasional debt | Public stock | Public stock |
Key Risks and Considerations Around Everlywell’s Value
Several factors can meaningfully affect Everlywell’s perceived net worth, including payer coverage changes, regulatory shifts in lab testing rules, competition from other at-home test providers, and broader telehealth utilization trends. Reimbursement policies from Medicare, Medicaid, and commercial insurers directly impact demand and pricing power. Additionally, consumer internet brands in wellness face marketing cost pressures and brand differentiation challenges. Because the company is private, disclosures are limited, so analysts must closely monitor new partnerships, membership trends, and adjustments in executive guidance when revising valuation estimates.
Bottom Line on Everlywell’s Net Worth and Strategic Position
Everlywell remains a large and well-funded player in at-home diagnostics and telehealth, with a valuation peaked above $1 billion in 2021 and a current estimated net worth likely positioned at a meaningful discount from that peak. The company’s diversified revenue from direct consumers, subscriptions, and enterprise programs provides multiple levers for growth, though margin discipline and retention will be critical. For investors, partners, and curious observers, understanding these drivers offers a durable framework for tracking Everlywell’s value over time without reliance on short-lived headlines.